Invivyd Data Shows Monoclonal Antibody Far Outperforms Vaccines in Tolerability

Event summary

  • Invivyd published a preprint comparing tolerability of its monoclonal antibody adintrevimab to COVID-19 vaccines, showing 2% Grade 2/3 systemic adverse events vs. 91.6% for mRNA vaccines.
  • The analysis re-examined EVADE trial data, comparing it to Sanofi's COMPARE study results presented at ESCMID on April 18, 2026.
  • Invivyd's upcoming LIBERTY trial will directly compare VYD2311 monoclonal antibody to mRNA vaccines in a head-to-head study.
  • The company aims to position monoclonal antibodies as safer alternatives to vaccines for COVID-19 protection.

The big picture

Invivyd's data challenges the vaccine-centric approach to COVID-19 protection by demonstrating significantly better tolerability for monoclonal antibodies. This positions the company at the forefront of a potential shift in preventive strategies, particularly for vulnerable populations. The upcoming LIBERTY trial results will be critical in determining whether this tolerability advantage can translate into broader market acceptance and regulatory approval.

What we're watching

Regulatory Pathway
Whether Invivyd can secure approval for VYD2311 based on tolerability advantages over existing vaccines.
Market Adoption
The pace at which healthcare providers and patients may prefer monoclonal antibodies over vaccines if tolerability data holds in LIBERTY trial.
Competitive Positioning
How Sanofi and other vaccine manufacturers may respond to this direct comparison of tolerability profiles.